The health-technology company Affinity AI is launching a peptide e-prescription marketplace, rolling out to 4,000 clinics and more than 20 compounding pharmacies. The launch is anchored by distribution partnerships with three networks — the American Peptide Association, Ola Digital Health, and Terri Ross Consulting — and brings the country's leading compounding pharmacies into a single portal. Affinity AI is free for clinics to join and connects buyers and sellers across the full catalog of compounded therapeutics, from peptides and GLP-1s to TRT, HRT, sexual health, and hair loss.
Affinity AI Launches B2B Marketplace for Compounded Peptides and GLP-1s

MIAMI, FL – July 19, 2026 – Affinity AI, a health-technology company building the first B2B marketplace for compounded-medication sourcing, today announced the launch of its Peptide eRx platform. The rollout — reaching 4,000 clinics and more than 20 compounding pharmacies at launch — marks a decisive step toward the company's mission: to make humanity healthier by making compounded-medication sourcing cheaper, safer, and faster.
At its core, Affinity AI is a marketplace. Clinics source medications; compounding pharmacies fulfill them. Think of it as the B2B Amazon for peptides, GLP-1s, TRT, HRT, sexual health, and hair loss — a single place where the people who prescribe compounded therapeutics can find, compare, and order from the pharmacies that make them.
A marketplace built on three promises: cheaper, safer, faster
The premise behind Affinity AI is simple, and it is one the company returns to at every turn: sourcing compounded medication today is harder than it should be and fixing that makes patients healthier.
Affinity AI is faster because, instead of logging into a dozen separate compounder portals — each with its own pricing, stock, dosages, shipping timelines, support, and compliance standards — a clinic can access dozens of compounders from one portal. Affinity AI is cheaper because, instead of a single clinic negotiating on the volume of a single clinic, the platform negotiates on the aggregate volume of thousands. And Affinity AI is safer because it brings every resource needed to validate compliance and product safety into one place — certificates of analysis, adverse-event records, state licensures, legitimate scripts, and the background of each pharmacist-in-charge.
The largest networks and the largest pharmacies, in one place
Affinity AI is rolling out through clinic networks it describes as among the largest in the field: the American Peptide Association, a peptide-certification body representing 2,000 peptide practitioners; Ola Digital Health, a telehealth platform supporting more than 70 telehealth clinics; and Terri Ross Consulting, a leading medspa consultancy with 2,000 students. Together, these partnerships put Affinity AI in front of thousands of the exact clinicians the platform was built to serve.
On the supply side, the platform launches with a roster of large compounding pharmacies — Empower Pharmacy, Strive Pharmacy, MediVera, Revive Rx, Perfect Rx, Promise Pharmacy, Striker Pharmacy, Optio Rx, The Pharmacy Hub, and Epiq Scripts — with more onboarding as the network expands.
Four features, one obsession
Ask what all of this looks like in practice, and Affinity AI points to four features:
First, one portal with more than 20 of the top compounding pharmacies, so clinics never have to switch between multiple systems again. Second, the best pricing in the market, so clinics can either widen their margins or pass the savings on to their patients. Third, automatic text and email updates on order status and shipping timelines, so clinics stop fielding the constant "where is my medication?" from patients. And fourth, "social-media-like" profiles for each compounder — surfacing that pharmacy's compliance credentials and unique value propositions — so clinics can order with the confidence that they are getting quality medications.
Running underneath every one of those features is the value Affinity AI heralds above all others: customer obsession. In Affinity AI's world, the customer is the clinician. Every design decision, every negotiation, and every line of the product is built around the person prescribing — because when the clinician's job gets easier, safer, and cheaper, the patient is the one who ultimately benefits.
"Our mission is to make humanity healthier, and the fastest path we've found to that is fixing the way compounded medication gets sourced," said Tim Yoon, Founder and CEO of Affinity AI. "Clinicians are the customer we are obsessed with. If we make their sourcing cheaper, safer, and faster, they can spend their energy on patients instead of portals — and that's how you move the needle on outcomes at scale."
Free to join
For all of it, clinics might reasonably expect a platform this capable to carry a steep cost. It doesn't. Affinity AI is 100% free to join.
The company generates revenue through a 15% service charge applied on top of the bulk pricing it has already negotiated with compounders — pricing that, even with the service charge included, still nets out cheaper than a clinic sourcing directly from those same pharmacies. The result is a straightforward proposition: better pricing, one portal, built-in compliance, and no cost to get started, which is what makes joining Affinity AI straightforward for most clinics.
Working shoulder to shoulder with providers
Affinity AI's founder remains hands-on with the clinicians the platform serves, continuing to work directly with providers to make the product better with every release. Clinicians, pharmacy partners, and telehealth operators who want to shape where Affinity AI goes next are invited to connect with and DM Tim Yoon on LinkedIn — he is still working closely with providers to make the product incredible, and the best ideas continue to come straight from the people using it.
About Affinity AI
Affinity AI is a health-technology company on a mission to make humanity healthier by making compounded-medication sourcing cheaper, safer, and faster. Through its Peptide eRx marketplace, Affinity AI connects clinics with the country's leading compounding pharmacies across peptides, GLP-1s, TRT, HRT, sexual health, and hair loss — bringing pricing, fulfillment, and compliance into a single portal. Built around an obsession with the clinician, Affinity AI aims to make sourcing effortless so that providers can focus on what matters most: their patients.
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Affinity AI launched a B2B marketplace for compounded peptides and GLP-1s, connecting 4,000 clinics with over 20 pharmacies. Its strategy focuses on making sourcing cheaper, safer, and faster by aggregating demand and centralizing compliance. The platform is free for clinics, generating revenue via a 15% service charge on negotiated bulk pricing, offering a competitive advantage through volume-based savings.
- Strategic partnerships with American Peptide Association, Ola Digital Health, and Terri Ross Consulting drive rapid clinic adoption.
- The platform's aggregated volume enables better pricing, enhancing clinic margins or patient savings.
PhD Lens: Clinical and outcomes impact
Affinity AI's Peptide eRx platform aims to enhance the safety and efficiency of sourcing compounded therapeutics, including peptides, GLP-1s, TRT, HRT, and sexual health medications. It centralizes critical compliance data like certificates of analysis, adverse-event records, and state licensures, allowing clinicians to validate product safety and pharmacist credentials from a single portal.
- The platform provides centralized access to certificates of analysis and adverse-event records for product safety validation.
- It streamlines compliance checks by consolidating state licensures and pharmacist-in-charge backgrounds.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.